Trials / Completed
CompletedNCT00043862
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will gather information on the effectiveness and safety of a treatment program for small cell lung cancer (SCLC) that uses an FDA approved chemotherapy combination, radiation therapy, and an oral investigational drug that may enhance the effects of radiation therapy. Study patients will receive two additional courses of the standard chemotherapy combination after completing radiation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | topotecan |
Timeline
- Start date
- 2002-08-01
- Primary completion
- 2005-11-01
- First posted
- 2002-08-15
- Last updated
- 2017-05-31
Locations
31 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00043862. Inclusion in this directory is not an endorsement.